This industry-supported symposium will address the unmet need for slowing or helping to prevent progression of long-term organ damage in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN), using the recently proposed disease modification definition in SLE/LN as a framework. By monitoring disease activity and organ damage outcomes throughout a patient’s disease course, the potential for and achievement of disease modification can be assessed, which after 5 years indicates that long-term organ damage progression has been reduced. The session will walk attendees through an interactive patient journey, alongside engaging case studies covering health disparities and potential detours that patients may encounter on their journey toward disease modification to help prevent organ damage. The case studies will include discussion about how to bring the patient back onto the path toward disease modification, as well as incorporating the patient voice to highlight the importance of shared decision-making within clinical practice. Developed and offered by GSK.
Non-CME
